These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
133 related articles for article (PubMed ID: 25755719)
1. Decreased expression of TFPI-2 correlated with increased expression of CD133 in cholangiocarcinoma. Chu X; Zhao P; Lv Y; Liu L Int J Clin Exp Pathol; 2015; 8(1):328-36. PubMed ID: 25755719 [TBL] [Abstract][Full Text] [Related]
2. CD133: a potential indicator for differentiation and prognosis of human cholangiocarcinoma. Fan L; He F; Liu H; Zhu J; Liu Y; Yin Z; Wang L; Guo Y; Wang Z; Yan Q; Huang G BMC Cancer; 2011 Jul; 11():320. PubMed ID: 21798073 [TBL] [Abstract][Full Text] [Related]
3. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis. Thanan R; Pairojkul C; Pinlaor S; Khuntikeo N; Wongkham C; Sripa B; Ma N; Vaeteewoottacharn K; Furukawa A; Kobayashi H; Hiraku Y; Oikawa S; Kawanishi S; Yongvanit P; Murata M Free Radic Biol Med; 2013 Dec; 65():1464-1472. PubMed ID: 23917144 [TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. Xi HQ; Zhao P J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057 [TBL] [Abstract][Full Text] [Related]
5. Inverse correlation of aberrant expression of fragile histidine triad (FHIT) protein with cyclin D1 protein and prognosis in Chinese patients with cholangiocarcinoma. Zhao P; Lu Y; Zhong M; Liu L; Li B Acta Oncol; 2008; 47(8):1557-63. PubMed ID: 18618300 [TBL] [Abstract][Full Text] [Related]
6. Clinical significance of stem cell marker CD133 expression in colorectal cancer. Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717 [TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance and prognostic value of CD133 expression in triple-negative breast carcinoma. Zhao P; Lu Y; Jiang X; Li X Cancer Sci; 2011 May; 102(5):1107-11. PubMed ID: 21276138 [TBL] [Abstract][Full Text] [Related]
8. Correlation of aPKC-iota and E-cadherin expression with invasion and prognosis of cholangiocarcinoma. Li Q; Wang JM; Liu C; Xiao BL; Lu JX; Zou SQ Hepatobiliary Pancreat Dis Int; 2008 Feb; 7(1):70-5. PubMed ID: 18234642 [TBL] [Abstract][Full Text] [Related]
9. Clinicopathologic significance of combined hepatocellular-cholangiocarcinoma with stem cell subtype components with reference to the expression of putative stem cell markers. Ikeda H; Harada K; Sato Y; Sasaki M; Yoneda N; Kitamura S; Sudo Y; Ooi A; Nakanuma Y Am J Clin Pathol; 2013 Sep; 140(3):329-40. PubMed ID: 23955451 [TBL] [Abstract][Full Text] [Related]
10. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma. Xu YF; Ge FJ; Han B; Yang XQ; Su H; Zhao AC; Zhao MH; Yang YB; Yang J World J Gastroenterol; 2015 Mar; 21(11):3256-65. PubMed ID: 25805932 [TBL] [Abstract][Full Text] [Related]
11. Strong expression of CD133 is associated with increased cholangiocarcinoma progression. Leelawat K; Thongtawee T; Narong S; Subwongcharoen S; Treepongkaruna SA World J Gastroenterol; 2011 Mar; 17(9):1192-8. PubMed ID: 21448425 [TBL] [Abstract][Full Text] [Related]
12. CA9 overexpression is an independent favorable prognostic marker in intrahepatic cholangiocarcinoma. Gu M Int J Clin Exp Pathol; 2015; 8(1):862-6. PubMed ID: 25755787 [TBL] [Abstract][Full Text] [Related]
13. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression. Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859 [TBL] [Abstract][Full Text] [Related]
14. Dyskerin expression in human fetal, adult and neoplastic intrahepatic bile ducts: correlations with cholangiocarcinoma aggressiveness. Vasuri F; Rocchi L; Degiovanni A; Giunchi F; Brandi G; Treré D; Montanaro L; D'Errico-Grigioni A Histopathology; 2015 Jan; 66(2):244-51. PubMed ID: 25367684 [TBL] [Abstract][Full Text] [Related]
15. Prognostic value of neutrophil distribution in cholangiocarcinoma. Mao ZY; Zhu GQ; Xiong M; Ren L; Bai L World J Gastroenterol; 2015 Apr; 21(16):4961-8. PubMed ID: 25945010 [TBL] [Abstract][Full Text] [Related]
16. CD133 and ALDH may be the molecular markers of cholangiocarcinoma stem cells. Wang M; Xiao J; Jiang J; Qin R Int J Cancer; 2011 Apr; 128(8):1996-7. PubMed ID: 20568110 [No Abstract] [Full Text] [Related]
17. Downregulated expression of PHLDA1 protein is associated with a malignant phenotype of cholangiocarcinoma. Zhao PO; Li X; Lu Y; Liu L Oncol Lett; 2015 Aug; 10(2):895-900. PubMed ID: 26622591 [TBL] [Abstract][Full Text] [Related]
18. Intrahepatic cholangiocarcinoma frequently shows loss of BAP1 and PBRM1 expression, and demonstrates specific clinicopathological and genetic characteristics with BAP1 loss. Misumi K; Hayashi A; Shibahara J; Arita J; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M Histopathology; 2017 Apr; 70(5):766-774. PubMed ID: 27864835 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma. Chen S; Hou JH; Feng XY; Zhang XS; Zhou ZW; Yun JP; Chen YB; Cai MY J Surg Oncol; 2013 Jun; 107(8):799-806. PubMed ID: 23609373 [TBL] [Abstract][Full Text] [Related]
20. CD133 expression is a potential prognostic indicator in intrahepatic cholangiocarcinoma. Shimada M; Sugimoto K; Iwahashi S; Utsunomiya T; Morine Y; Imura S; Ikemoto T J Gastroenterol; 2010 Aug; 45(8):896-902. PubMed ID: 20379837 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]